Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75 (Englisch)
- Neue Suche nach: Hu, Wen‐Yang
- Neue Suche nach: Xu, Liping
- Neue Suche nach: Chen, Bailing
- Neue Suche nach: Ou, Siyu
- Neue Suche nach: Muzzarelli, Kendall M.
- Neue Suche nach: Hu, Dan‐Ping
- Neue Suche nach: Li, Ye
- Neue Suche nach: Yang, Zhe
- Neue Suche nach: Vander Griend, Donald J.
- Neue Suche nach: Prins, Gail S.
- Neue Suche nach: Qin, Zhihui
- Neue Suche nach: Hu, Wen‐Yang
- Neue Suche nach: Xu, Liping
- Neue Suche nach: Chen, Bailing
- Neue Suche nach: Ou, Siyu
- Neue Suche nach: Muzzarelli, Kendall M.
- Neue Suche nach: Hu, Dan‐Ping
- Neue Suche nach: Li, Ye
- Neue Suche nach: Yang, Zhe
- Neue Suche nach: Vander Griend, Donald J.
- Neue Suche nach: Prins, Gail S.
- Neue Suche nach: Qin, Zhihui
In:
The Prostate
;
79
, 10
;
1166-1179
;
2019
- Aufsatz (Zeitschrift) / Elektronische Ressource
-
Titel:Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75
-
Beteiligte:Hu, Wen‐Yang ( Autor:in ) / Xu, Liping ( Autor:in ) / Chen, Bailing ( Autor:in ) / Ou, Siyu ( Autor:in ) / Muzzarelli, Kendall M. ( Autor:in ) / Hu, Dan‐Ping ( Autor:in ) / Li, Ye ( Autor:in ) / Yang, Zhe ( Autor:in ) / Vander Griend, Donald J. ( Autor:in ) / Prins, Gail S. ( Autor:in )
-
Erschienen in:The Prostate ; 79, 10 ; 1166-1179
-
Verlag:
-
Erscheinungsdatum:01.07.2019
-
Format / Umfang:14 pages
-
ISSN:
-
DOI:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Elektronische Ressource
-
Sprache:Englisch
-
Schlagwörter:
-
Datenquelle:
Inhaltsverzeichnis – Band 79, Ausgabe 10
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1063
-
Issue Information| 2019
- 1065
-
The influence of the presence of intraductal carcinoma of the prostate on the grade group system's prognostic performanceKato, Masashi / Hirakawa, Akihiro / Kobayashi, Yumiko Ms / Yamamoto, Akiyuki / Ishida, Ryo / Sano, Tomoyasu / Kimura, Tohru / Majima, Tsuyoshi / Ishida, Shohei / Funahashi, Yasuhito et al. | 2019
- 1071
-
An IL‐2 proaerolysin fusion toxin that selectively eliminates regulatory t cells to enhance antitumor immune responseRogers, Oliver / Yen, Hung / Solomon, Anna / Drake, Charles / Denmeade, Samuel et al. | 2019
- 1079
-
Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapyWu, Xiaoning / Scott, Helen / Carlsson, Sigrid V. / Sjoberg, Daniel D. / Cerundolo, Lucia / Lilja, Hans / Prevo, Remko / Rieunier, Guillaume / Macaulay, Valentine / Higgins, Geoffrey S. et al. | 2019
- 1090
-
Potential effect of anti‐inflammatory drug use on PSA kinetics and subsequent prostate cancer diagnosis: Risk stratification in black and white men with benign prostate biopsyKryvenko, Oleksandr N. / Wang, Yun / Sadasivan, Sudha / Gupta, Nilesh S. / Rogers, Craig / Bobbitt, Kevin / Chitale, Dhananjay A. / Rundle, Andrew / Tang, Deliang / Rybicki, Benjamin A. et al. | 2019
- 1099
-
Concept and benchmarks for assessing narrow‐sense validity of genetic risk score valuesYu, Hongjie / Shi, Zhuqing / Wu, Yishuo / Wang, Chi‐Hsiung / Lin, Xiaoling / Perschon, Chelsea / Isaacs, William B. / Helfand, Brian T. / Lilly Zheng, S. / Duggan, David et al. | 2019
- 1106
-
Patterns of response and progression in bone and soft tissue during and after treatment with radium‐223 for metastatic castrate‐resistant prostate cancerMcNamara, Megan Ann / Oyekunle, Taofik / Chin, Bennett B. / Oldan, Jorge / Anand, Aseem / Ritz, Michala / Shantzer, Lindsey / Anand, Monika / Armstrong, Andrew J. / George, Daniel J. et al. | 2019
- 1117
-
Association among plasma 1,25(OH)2D, ratio of 1,25(OH)2D to 25(OH)D, and prostate cancer aggressivenessRamakrishnan, Swathi / Steck, Susan E. / Arab, Lenore / Zhang, Hongmei / Bensen, Jeannette T. / Fontham, Elizabeth T. H. / Johnson, Candace S. / Mohler, James L. / Smith, Gary J. / Su, L. Joseph et al. | 2019
- 1125
-
The association of let‐7c, miR‐21, miR‐145, miR‐182, and miR‐221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low‐risk diseaseKurul, N. Ozgur / Ates, Ferhat / Yilmaz, Ismail / Narli, Gizem / Yesildal, Cumhur / Senkul, Temucin et al. | 2019
- 1133
-
Inflammatory mediators of prostate epithelial cells stimulated with Trichomonas vaginalis promote proliferative and invasive properties of prostate cancer cellsHan, Ik‐Hwan / Kim, Jung‐Hyun / Jang, Ki‐Seok / Ryu, Jae‐Sook et al. | 2019
- 1147
-
Cigarette smoking augments androgen receptor activity and promotes resistance to antiandrogen therapyShiota, Masaki / Ushijima, Miho / Imada, Kenjiro / Kashiwagi, Eiji / Takeuchi, Ario / Inokuchi, Junichi / Tatsugami, Katsunori / Kajioka, Shunichi / Eto, Masatoshi et al. | 2019
- 1156
-
SPOP and FOXA1 mutations are associated with PSA recurrence in ERG wt tumors, and SPOP downregulation with ERG‐rearranged prostate cancerHernández‐Llodrà, Silvia / Segalés, Laura / Safont, Ainara / Juanpere, Nuria / Lorenzo, Marta / Fumadó, Lluís / Rodríguez‐Vida, Alejo / Cecchini, Lluís / Bellmunt, Joaquim / Lloreta‐Trull, Josep et al. | 2019
- 1166
-
Targeting prostate cancer cells with enzalutamide‐HDAC inhibitor hybrid drug 2‐75Hu, Wen‐Yang / Xu, Liping / Chen, Bailing / Ou, Siyu / Muzzarelli, Kendall M. / Hu, Dan‐Ping / Li, Ye / Yang, Zhe / Vander Griend, Donald J. / Prins, Gail S. et al. | 2019
- 1180
-
IL‐8 protects prostate cancer cells from GSK‐3β‐induced oxidative stress by activating the mTOR signaling pathwaySun, Yi / Ai, Jian‐Zhong / Jin, Xi / Liu, Liang‐Ren / Lin, Tian‐Hai / Xu, Hang / Wei, Qiang / Yang, Lu et al. | 2019
- 1191
-
TMPRSS2‐ERG fusions linked to prostate cancer racial health disparities: A focus on AfricaBlackburn, James / Vecchiarelli, Stefano / Heyer, Erin E. / Patrick, Sean M. / Lyons, Ruth J. / Jaratlerdsiri, Weerachai / van Zyl, Smit / Bornman, M. S. Riana / Mercer, Tim R. / Hayes, Vanessa M. et al. | 2019